What Accelerator Life Science Partners does

Accelerator Life Science Partners (ALSP) is an early-stage life science accelerator and investment firm founded in 2003 (originally as Accelerator Corporation) that builds and finances next-generation biotechnology companies from academic science. The firm is headquartered in Seattle with offices in New York, San Diego, and Singapore, and operates a hands-on company-building model in which it licenses proprietary technologies from world-class research institutions (Rockefeller University, Weill Cornell Medicine, MD Anderson Cancer Center, Princeton University, Institute for Systems Biology, Case Western Reserve University, UT Southwestern), recruits scientific founders and management teams, and provides a full toolkit of business, scientific, and financial resources until portfolio companies graduate or exit. ALSP backs therapeutic platforms across oncology, neuroscience, metabolic disease, infectious disease, and CNS disorders, including ApoGen Biotechnologies, Automera (AUTAC-based protein degradation), KayoThera (retinoid pathway inhibitors), Proniras (tezampanel for opioid withdrawal), Magnolia Neurosciences, Lydian Neurosciences, Coba Therapeutics, and the ALSP Orchid Acquisition Corporation I SPAC. Three portfolio companies have been successfully acquired — Rodeo Therapeutics by Amgen for up to $721M, Lodo Therapeutics by Zymergen (now Ginkgo BioWorks), and Petra Pharma by an undisclosed global pharmaceutical company.

The firm generates returns through equity ownership in portfolio companies, realizing gains via strategic acquisitions, M&A, and the SPAC vehicle, supplemented by management fees and carried interest on its investment funds. Fund IV closed at $62.8M in 2015 with backing from AbbVie, Alexandria, ARCH, Eli Lilly, Pfizer Ventures, Johnson & Johnson Innovation, WuXi AppTec, and others; the firm has since launched additional financings for KayoThera, Automera, and Proniras totaling over $30M in disclosed rounds. ALSP is a minority-owned firm emphasizing diversity in healthcare, with a small senior team led by Senior Managing Director & Chairman Thong Q. Le and Managing Directors Kendall Mohler, PhD and Ian A.W. Howes, supported by an Operating Partners group and Clinical and Scientific Advisory Board. The platform operates with reported headcount of 1-10 in firmographics, though the disclosed leadership roster across four offices and active portfolio management is materially larger in practice.

Name

Accelerator Life Science Partners

Legal name

Accelerator Life Science Partners

Website

https://acceleratorlsp.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

1–10 employees

Short description

Accelerator Life Science Partners (ALSP), founded in 2003, is an early-stage life science accelerator that builds and finances biotech companies from academic research across oncology, neuroscience, and metabolic disease, generating returns through equity stakes, M&A exits, and a Nasdaq-listed SPAC.

Ownership category

akta.pro rank

Product category

Life Sciences Venture Capital

NAICS

Other Financial Investment Activities (5239), Portfolio Management and Investment Advice (523940), Management, Scientific, and Technical Consulting Services (5416)

SIC

Investment Advice (6282), Services-Management Consulting Services (8742)

akta.pro primary industry

Accelerators & Incubators (Investor-Operated) (FSANAAAM)

akta.pro secondary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

• Venture capital investing
• Biotech accelerator services
• Early-stage life sciences
• Company building services
• Biotechnology investment management

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Investment Returns from Portfolio Companies: Accelerator generates returns through equity investments in early-stage biotechnology companies. The firm takes equity stakes in portfolio companies and realizes returns through acquisitions (e.g., Amgen acquiring Rodeo for $721M, Zymergen acquiring Lodo Therapeutics) and successful exits. The firm also earns management fees and carried interest from its investment funds.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Accelerator Life Science Partners is an early-stage life science accelerator and investment firm that identifies, evaluates, finances, and manages the development of emerging biotechnology opportunities. The firm invests early in innovative science and serves as trusted partners to help move novel technologies from ideas to products, providing a complete toolkit including business, scientific, and financial resources to portfolio companies in exchange for equity ownership.

Product overview

Accelerator Life Science Partners (ALSP) is an early-stage life science accelerator and investment firm that builds and invests in biotechnology companies. Rather than a single unified product, ALSP operates as a company-building platform that provides investment capital, management expertise, scientific oversight, and operational resources to early-stage biotech startups. The portfolio includes 11 companies across various therapeutic areas: oncology (ApoGen, Automera, KayoThera, Petra Pharma), neuroscience (Magnolia Neurosciences, Lydian Neurosciences), metabolic diseases (KayoThera, Coba Therapeutics, Rodeo Therapeutics), infectious diseases (Lodo Therapeutics), and central nervous system disorders (Proniras). Three portfolio companies have been successfully acquired (Rodeo by Amgen, Petra Pharma, and Lodo by Zymergen). The firm also operates ALSP Orchid Acquisition Corporation I, a special purpose acquisition company (SPAC) focused on life sciences acquisitions.

Differentiator

Problem solved

Functional benefit

Products and services

• ApoGen Biotechnologies A biotechnology company developing a new class of therapeutics targeting drivers of cancer genomic mutations, building upon technologies developed at the University of Minnesota to develop drugs that block key pathways causing drug resistance.
• Automera An early-stage therapeutics company focused on the development of autophagy-targeting chimeras (AUTACs) for targeted protein degradation, augmented with quantum chemistry and AI-enabled drug discovery tools, with initial focus on oncology.
• KayoThera An early-stage therapeutics company developing first-in-class, oral small molecule inhibitors of the retinoid pathway for cancer immunotherapies and cardiometabolic diseases including diabetes and obesity.
• Proniras Corporation A clinical-stage biotechnology company developing novel small-molecule therapeutics for the treatment of substance use and specialty central nervous system disorders, with lead program PRN-001-01 (tezampanel) for opioid withdrawal.
• Magnolia Neurosciences A drug discovery and development company focused on creating a novel class of neuroprotective medicines for the treatment of neurodegeneration and neuronal injuries, launched in partnership with MD Anderson Cancer Center.
• Rodeo Therapeutics A biotechnology company focused on developing small-molecule therapies that increase tissue levels of prostaglandin PGE2 through modulation of 15-PGDH enzyme for tissue repair and regeneration; acquired by Amgen in March 2021 for up to $721 million.
• Petra Pharma A biotechnology company developing novel therapeutics that modulate phosphoinositide (PI) signaling pathways for cancer treatment; acquired by a global pharmaceutical company in 2020.
• Lodo Therapeutics A drug discovery company using a metagenomics-based platform to discover novel therapeutics from environmental microbial DNA for targeting undruggable diseases; acquired by Zymergen (now Ginkgo BioWorks).
• Lydian Neurosciences A biotechnology company focused on developing small molecules for the treatment of sleep disorders.
• Coba Therapeutics A biotechnology company developing novel therapeutics for the treatment of obesity and metabolic diseases.
• ALSP Orchid Acquisition Corporation I A blank check company (SPAC) formed to pursue acquisitions in healthcare and life sciences, with focus on investments in North America and Singapore in life science companies developing assets and next-generation platform technologies.

Quantifiable outcome

• Multiple successful exits including Amgen ($721M for Rodeo), Zymergen (Lodo), and undisclosed Petra Pharma acquisition
• +3 more outcomes

Named customers9 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered major and core.

• Indiana University School of MedicinemajorStrategic or Co-development Partner · 14 November 2024Clinical trial site conducting Proniras' Phase 1 clinical trial evaluating PRN-001-01 (tezampanel) for opioid withdrawal syndrome.
• Princeton UniversitycoreStrategic or Co-development Partner · 1 January 2019KayoThera founded based on discoveries from Dr. Mark Esposito's post-doctoral research and Professor Yibin Kang's research at Princeton University on retinoid pathway inhibition for cancer and metabolic diseases.
• Genentech (Roche Group)coreStrategic or Co-development Partner · 9 May 2018Strategic drug discovery collaboration where Genentech utilizes Lodo Therapeutics' proprietary genome mining and biosynthetic cluster assembly platform to identify novel molecules against multiple disease-related targets. Lodo eligible for up to $969M in upfront fees and milestone payments plus tiered royalties.
• MD Anderson Cancer CentercoreStrategic or Co-development Partner · 1 January 2017Co-founded Magnolia Neurosciences with The University of Texas MD Anderson Cancer Center to develop discoveries from scientists in MD Anderson's Therapeutics Discovery division and Neurodegeneration Consortium.
• Weill Cornell MedicinecoreStrategic or Co-development Partner · 1 January 2016Petra Pharma founded to advance cutting-edge research from Weill Cornell Medicine (Dr. Lewis Cantley) and established multi-year research alliance with Weill Cornell Medicine. Weill Cornell is a stakeholder in the company.
• Rockefeller UniversitycoreStrategic or Co-development Partner · 1 January 2015Licensing agreement with Rockefeller University for Lodo Therapeutics to practice and expand upon metagenomics technology platform developed by Dr. Sean Brady's laboratory. Bill & Melinda Gates Foundation sponsored research since 2014.
• Institute for Systems BiologycoreStrategic or Co-development Partner · 1 January 2014Founding institution partner providing scientific expertise and collaboration for Seattle-based operations.
• Talo Labs Pte LtdcoreStrategic or Co-development Partner · 1 January 2014Collaboration with Talo Labs Pte Ltd. to establish Automera for AUTAC platform development in Singapore.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Third Rock Ventures: Boston-based biotech venture builder that creates and launches early-stage life science companies from academic science, providing operational and scientific resources in a model nearly identical to ALSP's company-building approach.
• Flagship Pioneering: Cambridge-based venture creation firm that conceives, launches, and grows biotech platform companies (e.g., Moderna). Mirrors ALSP's "build rather than buy" thesis-creation model with deep operational support and dedicated founding teams.
• Atlas Venture: Boston/Cambridge-based early-stage life sciences VC that builds biotech companies from inception through Series A and beyond, providing hands-on operational support similar to ALSP's portfolio model.
• Versant Ventures: Healthcare-focused venture firm with a dedicated company-creation engine (e.g., Blueline Bioscience) that competes for the same academic translational opportunities as ALSP.
• Frazier Healthcare Partners: Seattle-based healthcare VC with a dedicated Life Sciences practice that creates and invests in early-stage biotech companies, with a similar translational model anchored in the Pacific Northwest research ecosystem.
• 5AM Ventures: Early-stage life sciences VC that partners with academic founders to build biotech companies, with a translational model that directly overlaps with ALSP's investment approach.
• ClavystBio: Singapore-based life sciences venture builder launched by Temasek to accelerate commercialization of biotech breakthroughs in Asia. Direct partner/co-lead on Automera and a regional peer in company-building.

Broad incumbents

• ARCH Venture Partners: Premier US life sciences VC that co-invests with ALSP (Magnolia, Proniras, Accelerator IV fund). A larger, broader player in early-stage biotech investing that overlaps with ALSP's sourcing strategy.
• OrbiMed: One of the largest dedicated healthcare investment firms globally, active across early- and late-stage biotech. A broader incumbent in life sciences venture investing with overlapping investment themes.

Others

• Alexandria Venture Investments: Strategic venture arm of Alexandria Real Estate Equities that co-invests with ALSP and provides lab facilities at Alexandria Center for Life Science. Functions as both a co-investor and an ecosystem/real-estate partner in NYC biotech.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/acceleratorcorp

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments12 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Accelerator Life Science Partners